Figure 2

Effect of anti-TIM-2 mAbs at different phases of CIA. (a-b) Exacerbation of collagen-induced arthritis (CIA) by RMT2-14 treatment. DBA/1 mice were immunized with primary type II collagen (CII)/complete Freund's adjuvant (CFA) on day 0 and secondary CII/incomplete Freund's adjuvant (IFA) on day 21. Two groups of mice were treated with RMT2-14 or control IgG every three days from day 0 to day 42. (a) Clinical score and (b) incidence of arthritis were evaluated from day 0. (c) Effect of anti-T cell immunoglobulin and mucin domain (TIM)-2 monoclonal antibodies (mAbs) at the early phase of CIA. Mice were immunized with CII/CFA once on day 0 and treated with RMT2-14, RMT2-25, RMT2-26, or control IgG from day 0 to day 17. Clinical score of arthritis was evaluated from day 0. (d) Effect of anti-TIM-2 mAbs at the late phase of CIA. Mice were immunized with CII/CFA once on day 0 and treated with RMT2-14, RMT2-25, RMT2-26, or control IgG from day 15 to day 32. Clinical score of arthritis was evaluated from day 0. Results are presented as the mean ± standard error of the mean of 10 mice in each group. *, P < 0.05 as compared with control IgG. Similar results were obtained in three independent experiments.